166 related articles for article (PubMed ID: 9838560)
1. A two-year study of the new cyclosporine formulation Consupren in de novo renal transplant patients.
Stephan AG; Barbari A; Masri M; Kamel G; Barakat Khoury W; Karam A; Mokhbat J; Kilany H
Transplant Proc; 1998 Nov; 30(7):3563-4. PubMed ID: 9838560
[No Abstract] [Full Text] [Related]
2. Acute allograft rejection following conversion to a new cyclosporine formulation in pediatric renal transplant patients.
Crocker J; Renton K; Wade A; McLellan H; Acott P
Transplant Proc; 1998 Aug; 30(5):2002-5. PubMed ID: 9723369
[No Abstract] [Full Text] [Related]
3. High performance liquid chromatography cyclosporine monitoring: a predictor of renal graft outcome.
Cicciarelli J; Avila D; Iwaki Y; Sather H; Mendez R
Transplant Proc; 1998 Aug; 30(5):1683-4. PubMed ID: 9723243
[No Abstract] [Full Text] [Related]
4. Evaluation of the new cyclosporine formulation, Consupren, in renal transplant patients.
Stephan AG; Barbari A; Masri MA; Rizk S; Moubarak R; Frem GJ; Kamel G; Baracat-Khoury W; Karam A
Transplant Proc; 1996 Jun; 28(3):1348-9. PubMed ID: 8658688
[No Abstract] [Full Text] [Related]
5. Measurement of lymphocyte cyclosporine levels in transplant patients.
Masri MA; Barbari A; Stephan A; Rizk S; Kilany H; Kamel G
Transplant Proc; 1998 Nov; 30(7):3561-2. PubMed ID: 9838559
[No Abstract] [Full Text] [Related]
6. A one-year comparative study of Neoral vs Consupren in de novo renal transplant patients.
Stephan A; Masri MA; Barbari A; Aoun S; Rizk S; Kamel G
Transplant Proc; 1998 Nov; 30(7):3533-4. PubMed ID: 9838547
[No Abstract] [Full Text] [Related]
7. Abbreviated cyclosporine pharmacokinetic profiling in clinical renal transplantation: from principles to practice.
Vathsala A; Lu YM
Transplant Proc; 2001; 33(7-8):3137-9. PubMed ID: 11750348
[No Abstract] [Full Text] [Related]
8. Cyclosporine pharmacokinetics in stable renal transplant patients: effect of formulation Sandimmun versus Consupren versus Neoral.
Masri MA; Barbari A; Stephan A; Kamel G; Frem G; Younan F; Rizk S; Moubarak R; Karam A
Transplant Proc; 1996 Jun; 28(3):1318-20. PubMed ID: 8658676
[No Abstract] [Full Text] [Related]
9. Long-term experience with Sandimmun Neoral: results in de novo and stable renal transplant patients after 24-month treatment. The German Neoral Study Group.
Korn A; Färber L; Maibücher A; Buchholz B; Offermann G
Transplant Proc; 1997 Nov; 29(7):2945-7. PubMed ID: 9365623
[No Abstract] [Full Text] [Related]
10. Neoral versus Sandimmune in kidney transplantation.
Tisone G; Orlando G; Mercadante E; Vennarecci G; Pisani F; Buonomo O; Negrini S; Casciani CU
Transplant Proc; 1998 Aug; 30(5):1749-50. PubMed ID: 9723265
[No Abstract] [Full Text] [Related]
11. Conversion of stable renal transplant recipients from Sandimmune to Sang-35, a novel cyclosporine formulation, using a dose-normalized equivalence method.
First MR; Weiskittel P; Burton M; Shah M; Dreyer D; Fleck P; Bey C; Peddi R; Canafax D; Schroeder TJ
Transplant Proc; 1998 Aug; 30(5):1701-5. PubMed ID: 9723249
[No Abstract] [Full Text] [Related]
12. Variability of Sandimmune pharmacokinetics in renal transplant patients.
Wingerchuk C; Heim-Duthoy KL; Macres MG; Kasiske BL
Transplant Proc; 1998 Aug; 30(5):1656-7. PubMed ID: 9723230
[No Abstract] [Full Text] [Related]
13. Cyclosporine lymphocyte level and lymphocyte count: new guidelines for tailoring immunosuppressive therapy.
Barbari A; Stephan A; Masri M; Mourad N; Kamel G; Kilani H; Karam A; Daya IA
Transplant Proc; 2003 Nov; 35(7):2742-4. PubMed ID: 14612101
[No Abstract] [Full Text] [Related]
14. Safety and effectiveness of microemulsion cyclosporine in renal allograft recipients: 1-year follow-up study.
Park K; Kim MS; Kim SI; Kim YS; Moon JI
Transplant Proc; 1998 Nov; 30(7):3556-7. PubMed ID: 9838557
[No Abstract] [Full Text] [Related]
15. Low exposure to cyclosporine is a risk factor for the occurrence of chronic rejection after kidney transplantation.
Citterio F; Torricelli P; Serino F; Foco M; Pozzetto U; Fioravanti P; Castagneto M
Transplant Proc; 1998 Aug; 30(5):1688-90. PubMed ID: 9723245
[No Abstract] [Full Text] [Related]
16. C2 single-point sampling to evaluate cyclosporine exposure in long-term renal transplant recipients.
Citterio F; Scatà MC; Borzi MT; Pozzetto U; Castagneto M
Transplant Proc; 2001; 33(7-8):3133-6. PubMed ID: 11750347
[No Abstract] [Full Text] [Related]
17. Conversion from conventional Sandimmun to Neoral therapy in stable renal transplant recipients.
Løkkegaard H; Asmundsson P; Clausen P; Dieperink H; Hansen JM; Heaf J; Jensen SB; Kornerup HJ; Madsen S; Pedersen EB; Poulsen JV; Rasmussen K
Transplant Proc; 1996 Aug; 28(4):2199-201. PubMed ID: 8769199
[No Abstract] [Full Text] [Related]
18. Relationship between maintenance dose of cyclosporine and long-term kidney graft survival. Collaborative Transplant Study.
Opelz G
Transplant Proc; 1998 Aug; 30(5):1716-7. PubMed ID: 9723253
[No Abstract] [Full Text] [Related]
19. Effect of subclinical rejection on renal allograft histology and function at 6 months.
Rush D; Jeffery J; Trpkov K; Solez K; Gough J
Transplant Proc; 1996 Feb; 28(1):494-5. PubMed ID: 8644325
[No Abstract] [Full Text] [Related]
20. Cyclosporine microemulsion formulation (Neoral) in transplantation: pharmacokinetic/pharmacodynamic relationships.
Mueller EA; Niese D; Mellein B
Transplant Proc; 1998 Aug; 30(5):1694-6. PubMed ID: 9723247
[No Abstract] [Full Text] [Related]
[Next] [New Search]
